UCB SA
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, … Read more
UCB SA (UCBJF) - Net Assets
Latest net assets as of December 2025: $10.86 Billion USD
Based on the latest financial reports, UCB SA (UCBJF) has net assets worth $10.86 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($18.15 Billion) and total liabilities ($7.29 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $10.86 Billion |
| % of Total Assets | 59.85% |
| Annual Growth Rate | 8.79% |
| 5-Year Change | 29.54% |
| 10-Year Change | 98.34% |
| Growth Volatility | 20.25 |
UCB SA - Net Assets Trend (2002–2025)
This chart illustrates how UCB SA's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for UCB SA (2002–2025)
The table below shows the annual net assets of UCB SA from 2002 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $10.86 Billion | +8.32% |
| 2024-12-31 | $10.03 Billion | +11.74% |
| 2023-12-31 | $8.97 Billion | -0.98% |
| 2022-12-31 | $9.06 Billion | +8.08% |
| 2021-12-31 | $8.39 Billion | +15.32% |
| 2020-12-31 | $7.27 Billion | +3.75% |
| 2019-12-31 | $7.01 Billion | +12.05% |
| 2018-12-31 | $6.25 Billion | +9.05% |
| 2017-12-31 | $5.74 Billion | +4.73% |
| 2016-12-31 | $5.48 Billion | -1.24% |
| 2015-12-31 | $5.55 Billion | +14.54% |
| 2014-12-31 | $4.84 Billion | +5.22% |
| 2013-12-31 | $4.60 Billion | +0.20% |
| 2012-12-31 | $4.59 Billion | -4.77% |
| 2011-12-31 | $4.82 Billion | +5.03% |
| 2010-12-31 | $4.59 Billion | +3.96% |
| 2009-12-31 | $4.42 Billion | +9.96% |
| 2008-12-31 | $4.02 Billion | -5.79% |
| 2007-12-31 | $4.26 Billion | -10.76% |
| 2006-12-31 | $4.78 Billion | +98.34% |
| 2005-12-31 | $2.41 Billion | +22.60% |
| 2004-12-31 | $1.96 Billion | +10.16% |
| 2003-12-31 | $1.78 Billion | +13.96% |
| 2002-12-31 | $1.57 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to UCB SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 867574937600.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $8.68 Billion | 79.87% |
| Common Stock | $583.78 Million | 5.37% |
| Other Comprehensive Income | $-36.99 Million | -0.34% |
| Other Components | $1.64 Billion | 15.10% |
| Total Equity | $10.86 Billion | 100.00% |
UCB SA Competitors by Market Cap
The table below lists competitors of UCB SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Banco Bradesco S.A.
SA:BBDC3
|
$20.38 Billion |
|
Schindler Holding AG
PINK:SHLAF
|
$20.43 Billion |
|
Halma PLC
PINK:HALMY
|
$20.44 Billion |
|
Humana Inc
NYSE:HUM
|
$20.50 Billion |
|
Sandvik AB (publ)
PINK:SDVKF
|
$20.36 Billion |
|
First Solar Inc
NASDAQ:FSLR
|
$20.32 Billion |
|
Gree Electric Appliances Inc of Zhuhai
SHE:000651
|
$20.32 Billion |
|
Great Wall Motor Company Ltd
PINK:GWLLY
|
$20.31 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in UCB SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 10,029,000,000 to 10,862,929,884, a change of 833,929,884 (8.3%).
- Net income of 1,557,416,468 contributed positively to equity growth.
- Dividend payments of 264,000,000 reduced retained earnings.
- Share repurchases of 121,000,000 reduced equity.
- Other comprehensive income decreased equity by 440,986,142.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $1.56 Billion | +14.34% |
| Dividends Paid | $264.00 Million | -2.43% |
| Share Repurchases | $121.00 Million | -1.11% |
| Other Comprehensive Income | $-440.99 Million | -4.06% |
| Other Changes | $102.50 Million | +0.94% |
| Total Change | $- | 8.32% |
Book Value vs Market Value Analysis
This analysis compares UCB SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.97x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 10.05x to 2.97x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-12-31 | $16.92 | $170.00 | x |
| 2003-12-31 | $24.45 | $170.00 | x |
| 2004-12-31 | $26.79 | $170.00 | x |
| 2005-12-31 | $32.97 | $170.00 | x |
| 2006-12-31 | $61.92 | $170.00 | x |
| 2007-12-31 | $46.50 | $170.00 | x |
| 2008-12-31 | $43.96 | $170.00 | x |
| 2009-12-31 | $47.36 | $170.00 | x |
| 2010-12-31 | $49.84 | $170.00 | x |
| 2011-12-31 | $50.35 | $170.00 | x |
| 2012-12-31 | $51.23 | $170.00 | x |
| 2013-12-31 | $47.64 | $170.00 | x |
| 2014-12-31 | $52.53 | $170.00 | x |
| 2015-12-31 | $59.06 | $170.00 | x |
| 2016-12-31 | $59.29 | $170.00 | x |
| 2017-12-31 | $61.75 | $170.00 | x |
| 2018-12-31 | $66.96 | $170.00 | x |
| 2019-12-31 | $37.60 | $170.00 | x |
| 2020-12-31 | $37.43 | $170.00 | x |
| 2021-12-31 | $43.19 | $170.00 | x |
| 2022-12-31 | $46.52 | $170.00 | x |
| 2023-12-31 | $45.98 | $170.00 | x |
| 2024-12-31 | $51.55 | $170.00 | x |
| 2025-12-31 | $57.17 | $170.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently UCB SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 14.34%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 20.13%
- • Asset Turnover: 0.43x
- • Equity Multiplier: 1.67x
- Recent ROE (14.34%) is above the historical average (10.27%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 21.50% | 5.89% | 2.15x | 1.70x | $177.72 Million |
| 2003 | 18.96% | 10.16% | 1.08x | 1.73x | $159.77 Million |
| 2004 | 16.73% | 9.25% | 0.66x | 2.75x | $131.55 Million |
| 2005 | 31.34% | 32.25% | 0.50x | 1.96x | $514.10 Million |
| 2006 | 8.02% | 14.55% | 0.24x | 2.30x | $-90.40 Million |
| 2007 | 3.75% | 4.41% | 0.38x | 2.24x | $-266.30 Million |
| 2008 | 1.05% | 1.17% | 0.38x | 2.37x | $-359.30 Million |
| 2009 | 11.62% | 16.46% | 0.34x | 2.07x | $71.50 Million |
| 2010 | 2.24% | 3.20% | 0.36x | 1.95x | $-356.00 Million |
| 2011 | 4.94% | 7.33% | 0.35x | 1.90x | $-244.10 Million |
| 2012 | 5.42% | 7.19% | 0.37x | 2.04x | $-210.40 Million |
| 2013 | 3.48% | 4.69% | 0.34x | 2.15x | $-300.30 Million |
| 2014 | 4.18% | 6.25% | 0.33x | 2.03x | $-291.20 Million |
| 2015 | 10.98% | 16.07% | 0.35x | 1.93x | $55.80 Million |
| 2016 | 9.31% | 12.45% | 0.41x | 1.83x | $-38.40 Million |
| 2017 | 12.95% | 16.62% | 0.46x | 1.71x | $171.70 Million |
| 2018 | 12.68% | 17.27% | 0.44x | 1.67x | $169.00 Million |
| 2019 | 11.25% | 16.12% | 0.44x | 1.57x | $88.10 Million |
| 2020 | 10.07% | 13.69% | 0.40x | 1.83x | $4.90 Million |
| 2021 | 12.62% | 18.31% | 0.41x | 1.69x | $219.40 Million |
| 2022 | 4.61% | 7.58% | 0.35x | 1.75x | $-488.40 Million |
| 2023 | 3.82% | 6.53% | 0.34x | 1.73x | $-554.50 Million |
| 2024 | 10.62% | 17.31% | 0.35x | 1.73x | $62.10 Million |
| 2025 | 14.34% | 20.13% | 0.43x | 1.67x | $471.12 Million |
Industry Comparison
This section compares UCB SA's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| UCB SA (UCBJF) | $10.86 Billion | 21.50% | 0.67x | $20.38 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |